S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Forecast & News

$110.42
-2.05 (-1.82 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$109.72
Now: $110.42
$113.79
50-Day Range
$105.09
MA: $110.04
$115.44
52-Week Range
$92.56
Now: $110.42
$141.86
Volume1.51 million shs
Average Volume1.80 million shs
Market Capitalization$24.43 billion
P/E Ratio15.57
Dividend YieldN/A
Beta1.67
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 billion
Cash Flow$9.12 per share
Book Value$41.08 per share

Profitability

Net Income$77.60 million

Miscellaneous

Employees2,656
Market Cap$24.43 billion
Next Earnings Date2/3/2020 (Estimated)
OptionableOptionable

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.


Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Wednesday, October, 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.47 by $0.32. The biopharmaceutical company earned $1.26 billion during the quarter, compared to analyst estimates of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The company's revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.02 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY19 earnings guidance on Wednesday, October, 23rd. The company provided earnings per share guidance of $10.25-10.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.93. The company issued revenue guidance of $4.86-4.89 billion, compared to the consensus revenue estimate of $4.84 billion.

What price target have analysts set for ALXN?

19 Wall Street analysts have issued 1-year price targets for Alexion Pharmaceuticals' shares. Their forecasts range from $125.00 to $186.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $156.89 in the next year. This suggests a possible upside of 42.1% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

What is the consensus analysts' recommendation for Alexion Pharmaceuticals?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Has Alexion Pharmaceuticals been receiving favorable news coverage?

Media stories about ALXN stock have trended neutral on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Alexion Pharmaceuticals.

Are investors shorting Alexion Pharmaceuticals?

Alexion Pharmaceuticals saw a increase in short interest in November. As of November 29th, there was short interest totalling 4,250,000 shares, an increase of 16.8% from the November 14th total of 3,640,000 shares. Based on an average daily trading volume, of 1,840,000 shares, the short-interest ratio is currently 2.3 days. Currently, 1.9% of the company's shares are short sold. View Alexion Pharmaceuticals' Current Options Chain.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Celgene (CELG), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), UnitedHealth Group (UNH) and Broadcom (AVGO).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 56)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
  • Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)
  • Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62)

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (4.91%), Orbimed Advisors LLC (0.75%), Redmile Group LLC (0.53%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Pictet Asset Management Ltd. (0.42%) and First Trust Advisors LP (0.30%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., First Trust Advisors LP, Orbimed Advisors LLC, State Street Corp, State of Tennessee Treasury Department, State of New Jersey Common Pension Fund D, Calamos Advisors LLC and Parametric Portfolio Associates LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Worldquant Millennium Advisors LLC, Man Group plc, Point72 Asset Management L.P., Krensavage Asset Management LLC, Phoenix Holdings Ltd., Squarepoint Ops LLC and Empire Life Investments Inc.. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $110.42.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $24.43 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.60 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.View Additional Information About Alexion Pharmaceuticals.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]


MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,167 (Vote Outperform)
Underperform Votes:  669 (Vote Underperform)
Total Votes:  1,836
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel